Beyond the Liver Trap: How Pragmatic Chemistry Could Upend RNA Delivery

NANTONG, China – October 23, 2026 — For the past decade, genetic medicine has been effectively quarantined in the liver. While GalNAc conjugation turned hepatic RNA silencing into a commercial reality, the quest to deliver oligonucleotides to the heart, skeletal muscle, and adipose tissue has been fraught with structural complexity. We have seen the rise of bulky antibody-oligonucleotide conjugates (AOCs) and fragile lipid nanoparticles (LNPs)—both of which carry significant manufacturing and tolerability burdens.

Today, a peer-reviewed study published in Molecular Therapy – Nucleic Acids by clinical-stage biopharmaceutical company Ractigen Therapeutics suggests a more elegant, pragmatic path forward. Detailing the preclinical and structural mechanics of its LiCO (Lipid-Conjugated Oligonucleotide) platform, the company demonstrates that a single-entity lipid conjugate, synthesized via standard solid-phase chemistry, can achieve multi-month extrahepatic delivery. For an industry wrestling with the cost and scale of complex biologics, this pivot back to simplified chemistry warrants a critical assessment.

Breaking the Barrier with Pragmatic Chemistry

The biological hurdle is well documented: the liver naturally traps circulating macromolecules. To bypass this "liver trap," competitors like Dyne Therapeutics and Avidity Biosciences have engineered AOCs that tether synthetic oligonucleotides to large monoclonal antibodies targeting the transferrin receptor 1 (TfR1). While scientifically sound, AOCs are a manufacturing labyrinth. They require producing a GMP-grade biologic, synthesizing an oligonucleotide, and executing a highly controlled conjugation step that often yields heterogeneous drug-to-antibody ratios and purification bottlenecks.

Conversely, the newly published data on the LiCO platform outlines a dramatically simplified architecture. The technology pairs an optimized lipid moiety with a proprietary benzimidazole-based (SDL) linker at the 5′ end of the passenger strand. Because it is a chemically defined, single-entity molecule, it can be manufactured entirely through automated solid-phase synthesis.

Industry experts note that while solid-phase chemistry faces its own long-term scalability limits regarding solvent waste at metric-ton scales, it fundamentally sidesteps the batch-to-batch inconsistencies and encapsulation failures inherent to multi-component LNPs. The resulting product is a stable, easily purified molecule that does not require the strict cold-chain logistics of LNPs or the complex analytical characterization of AOCs.

The CD36 Mechanism and a Dual-Front Attack on Duchenne

The Molecular Therapy paper elucidates exactly how this simplified molecule navigates the body. Mechanistic studies in knockout models reveal that the platform's tissue tropism is driven by CD36, a fatty acid translocase receptor highly expressed in metabolically active tissues. In mice, a single systemic dose drove greater than 90% target mRNA knockdown across skeletal muscle, the heart, the aorta, and adipose tissue. Crucially, hepatic activity cleared rapidly, leaving a functional depot in the target extrahepatic tissues that maintained at least 50% silencing for six months.

The clinical implications of this dual muscle-and-heart tropism are profound, particularly for Duchenne muscular dystrophy (DMD). DMD morbidity is not solely driven by skeletal muscle degeneration; fatal cardiac failure is a primary endpoint of the disease. Consequently, therapies that fail to adequately penetrate the myocardium leave a critical vulnerability unaddressed.

Ractigen is currently testing this hypothesis in humans with RAG-18, a systemic therapy built on the LiCO architecture. Data presented earlier this month at the 2026 World Muscle Society Congress provided the first clinical proof-of-mechanism for the platform. Paired biopsies at Day 113 showed up to a 5.3-fold increase in sarcolemmal utrophin expression, accompanied by reductions in thigh muscle MRI T2 relaxation times.

"Skeletal muscle, cardiac tissue, and adipose tissue sit at the center of a vast spectrum of human diseases—from devastating neuromuscular and cardiovascular disorders to global metabolic syndromes—yet they have remained largely out of reach for conventional oligonucleotide chemistry," stated Long-Cheng Li, M.D., Founder and CEO of Ractigen Therapeutics.

Beyond Silencing: The Rise of Gene Activation

While the delivery mechanism is the structural headline, the payload represents an equally significant strategic shift. The vast majority of RNA platforms, including Alnylam's pioneering therapies, focus on small interfering RNA (siRNA) to silence disease-causing genes. Ractigen, however, is utilizing the LiCO platform to deliver small activating RNA (saRNA)—turning genes on rather than off.

In the case of RAG-18, the payload transcriptionally upregulates the UTRN gene to produce utrophin, a protein structurally similar to the dystrophin missing in DMD patients. Because it activates a compensatory gene rather than attempting to edit or replace a mutated one, the therapy is inherently mutation-agnostic, potentially serving the entire DMD patient population.

This activation strategy is also being deployed locally in oncology. Ractigen's RAG-01 program utilizes the same lipid-conjugate technology for intravesical delivery to the bladder urothelium, targeting non-muscle invasive bladder cancer (NMIBC). Rather than silencing a tumor promoter, RAG-01 activates the tumor suppressor gene CDKN1A (p21). Preliminary Phase I data presented at the 2025 European Association of Urology Congress demonstrated a 66.7% complete response rate in carcinoma in situ patients who had previously failed standard BCG therapy, all while maintaining minimal systemic exposure.

Execution Over Hype in the Clinical Trenches

The transition from elegant preclinical models to messy human biology is where many promising platforms falter. The translation of the LiCO platform into the clinic offers a transparent look at this reality. While the early data for RAG-18 proved that the drug reaches the muscle and activates the target gene—a monumental technical achievement—the functional outcomes in the small, three-patient cohort were mixed. One participant improved in the 6-minute walk test, another remained stable, and a third declined, while overall functional assessment scores dropped slightly across the board.

These early clinical nuances underscore the difference between proof-of-mechanism and definitive clinical efficacy. However, from a strategic standpoint, a delivery platform that can safely deposit active genetic payloads into the heart and skeletal muscle without relying on immunogenic viral vectors, fragile lipid formulations, or complex antibody conjugates is a massive operational advantage. By anchoring its delivery strategy in scalable, single-entity chemistry, the company has bypassed the most notorious manufacturing bottlenecks in advanced therapeutics, setting a new baseline for what is commercially and practically viable in extrahepatic genetic medicine.